Literature DB >> 17573514

Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.

Victor F Tapson1, Hervé Decousus, Mario Pini, Beng H Chong, James B Froehlich, Manuel Monreal, Alex C Spyropoulos, Geno J Merli, Rainer B Zotz, Jean-François Bergmann, Ricardo Pavanello, Alexander G G Turpie, Mashio Nakamura, Franco Piovella, Ajay K Kakkar, Frederick A Spencer, Gordon Fitzgerald, Frederick A Anderson.   

Abstract

BACKGROUND: Evidence-based guidelines recommend that acutely ill hospitalized medical patients who are at risk of venous thromboembolism (VTE) should receive prophylaxis. Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE).
METHODS: IMPROVE is an ongoing, multinational, observational study. Participating hospitals enroll the first 10 consecutive eligible acutely ill medical patients each month. Patient management is determined by the treating physicians. An analysis of data on VTE prophylaxis practices is presented.
RESULTS: From July 2002 to September 30, 2006, 15,156 patients were enrolled from 52 hospitals in 12 countries, of whom 50% received in-hospital pharmacologic and/or mechanical VTE prophylaxis. In the United States and other participating countries, 52% and 43% of patients, respectively, should have received prophylaxis according to guideline recommendations from the American College of Chest Physicians (ACCP). Only approximately 60% of patients who either met the ACCP criteria for requiring prophylaxis or were eligible for enrollment in randomized clinical trials that have shown the benefits of pharmacologic prophylaxis actually received prophylaxis. Practices varied considerably. Intermittent pneumatic compression was the most common form of medical prophylaxis utilized in the United States, although it was used very rarely in other countries (22% vs 0.2%, respectively). Unfractionated heparin was the most frequent pharmacologic approach used in the United States (21% of patients), with low-molecular-weight heparin used most frequently in other participating countries (40%). There was also variable use of elastic stockings in the United States and other participating countries (3% vs 7%, respectively).
CONCLUSIONS: Our data suggest that physicians' practices for providing VTE prophylaxis to acutely ill hospitalized medical patients are suboptimal and highlight the need for improved implementation of existing evidence-based guidelines in hospitals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573514     DOI: 10.1378/chest.06-2993

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  117 in total

Review 1.  Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.

Authors:  G Eymin; A K Jaffer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 2.  Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing.

Authors:  Charles E Mahan; Mario Pini; Alex C Spyropoulos
Journal:  Intern Emerg Med       Date:  2010-02-23       Impact factor: 3.397

3.  Variation in physician deep vein thrombosis prophylaxis attitudes and practices at an academic tertiary care center.

Authors:  Erin M Galbraith; Bonnie M Vautaw; Mary Grzybowski; Peter K Henke; Tomas W Wakefield; James B Froehlich
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

4.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Venous thromboembolism prophylaxis among medical patients at US hospitals.

Authors:  Michael B Rothberg; Maureen Lahti; Penelope S Pekow; Peter K Lindenauer
Journal:  J Gen Intern Med       Date:  2010-03-30       Impact factor: 5.128

6.  Venous thromboembolism in COPD hospitalized patients.

Authors:  Raquel Barba; Antonio Zapatero; Javier Marco; Juan E Losa; Susana Plaza; Jose Manuel Casas; Jesús Canora
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

7.  Prophylaxis of venous thromboembolism in elderly patients with multimorbidity.

Authors:  Maura Marcucci; Alfonso Iorio; Alessandro Nobili; Mauro Tettamanti; Luca Pasina; Codjo Djignefa Djade; Alessandra Marengoni; Francesco Salerno; Salvatore Corrao; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2013-05-08       Impact factor: 3.397

8.  Venous thromboembolism prophylaxis in hospitalized patients with pneumonia: a prospective survey.

Authors:  Petra Jancar; Tina Morgan; Ales Mrhar; Mitja Kosnik; Mitja Lainscak
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

9.  Adherence to thromboprophylaxis guidelines in elderly patients with hospital acquired venous thromboembolism: a case control study.

Authors:  Jason Suh; Amishi Desai; Anish Desai; Josephine Dela Cruz; Anusiyanthan Mariampillai; Alexander Hindenburg
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

Review 10.  Impact on patient care: patient case through the continuum of care.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.